MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors
Year: 2014
Type: article
Abstract: // Yuan-Shuo Hsueh 1 , Hui Hua Chang 2 , Nai-Jung Chiang 1,3 , Chueh-Chuan Yen 4,5 , Chien-Feng Li 1,6,7,8 and Li-Tzong Chen 1,2,3,9 1 National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan 2 Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan 3 Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan 4 Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan 5 National Yang-Ming University School of Medicine, Taipei, Taiwan 6 Department of Pathology, Chi-Mei Foundation Medical Center, Tainan, Taiwan 7 Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan 8 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 9 Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwann Correspondence: Li-Tzong Chen, email: // Chien-Feng Li, email: // Keywords : gastrointestinal stromal tumor, KIT, heat shock protein 90 inhibitor, MTOR inhibitor, autophagy Received : June 19, 2014 Accepted : October 21, 2014 Published : October 21, 2014 Abstract Our previous study demonstrated NVP-AUY922, a HSP90AA1 inhibitor, could enhance mutant KIT degradation in gastrointestinal stromal tumor (GIST) cells through both proteasome- and autophagy-mediated pathways. Herein, we showed rapamycin, a MTOR inhibitor and autophagy inducer, could reduce total and phospho-KIT expression levels and enhance apoptosis in imatinib-resistant GIST cells. The involvement of autophagy in rapamycin-induced KIT downregulation was further confirmed by co-localization of KIT and autophagosome, and partial recovery of KIT expression level by either siRNA-mediated BECN1 and ATG5 silencing or autophagy inhibitors after rapamycin. Rapamycin and NVP-AUY922 synergistically inhibited GIST cells growth in vitro . The combination of low-dose NVP-AUY922 with rapamycin had comparable effects on reducing KIT expression, increasing MAP1LC3B puncta and tumor necrosis, and inhibiting tumor growth as high-dose NVP-AUY922 did in GIST430 xenograft model. Our results suggest the addition of a MTOR inhibitor may reduce NVP-AUY922 dose requirement and potentially improve its therapeutic index in mutant KIT-expressing GISTs.
Source: Oncotarget
Institutions: National Health Research Institutes, National Cheng Kung University, National Cheng Kung University Hospital, Taipei Veterans General Hospital, National Yang Ming University, Kaohsiung Medical University, Chi Mei Medical Center, Southern Taiwan University of Science and Technology, Kaohsiung Medical University Chung-Ho Memorial Hospital
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W1732266052
